Alleviation of Side Effects Associated with Best Practice Combination Therapies

TEAE (Safety Population) SWISH Study
• Phase II single-arm trial evaluated prophylaxis with steroid mouthwash on everolimus-associated stomatitis 
Novel Agents and Emerging Clinical Data for HR+ Breast Cancer
Full Population
PD-1/L1 Immunotherapy in Breast Cancer
• Immune checkpoint inhibitors are effective in a variety of solid tumors • In the metastatic setting: -20% ORR in TNBC 1,2 -6-12% ORR in ER+ BC 3, 4 • In ER+ mBC resistant to endocrine therapy, total mutational burden increases 5 , but these tumors are still generally immunologically 'cold' • Immunotherapy combination strategies that increase immune recognition through enhanced antigen presentation and/or increased T cell homing may increase immunotherapy response 
Kinase Domain
Acquired (not observed in primary tumor) Shared (also observed in primary tumor) Unknown (primary tumor status unknown) ERBB2 ERBB2 mutations in 7% 83% of ERBB2 mutations (5/6) in metastatic samples with matched primaries were acquired.
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Use of Novel Combination Therapies in the Treatment of Advanced HR+/HER2-Breast Cancer
